Psychiatr. pro Praxi, 2006; 1: 12-14

INTERESTING „UNKNOWN“ VALPROIC ACID

MUDr. Robert Matička
Psychiatrická ambulance, Praha

Valproic acid has been used like mood stabiliser for a long time, there is efficacy at mood stabilizing and treatment of BAP. However there is unclear the distinct mechanism of efficacy at BAP treatment. A lot of effects of valproic acid are known on subcellular degree, even with the influence on CNS plasticity.

Keywords: Key words: valproic acid, mood stabilizers, BAP, CNS plasticity.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matička R. INTERESTING „UNKNOWN“ VALPROIC ACID. Psychiatr. praxi. 2006;7(1):12-14.
Download citation

References

  1. Balfour JA, Brusin HM. Valproic Acid a review od its pharmacology and therapeutic potencial in indications other than epilepsy. CNS Drugs, 2, 1994; 2: 144-173. Go to original source...
  2. Bareš M, Linhartová L. Lithium, valproát a karbamazepin v léčbě bipolární afektivní poruchy v graviditě a v období po porodu. Praktický lékař 81, 2001; 11: 645-648.
  3. Bosetti F, Weerasinghe GR, Rosenberger TA, Rapoport SI. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. Journal of Neurochemistry, 2003; 85: 690-696. Go to original source... Go to PubMed...
  4. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs. Lithium and placebo in the treatment of mania. Jama, 1994; 271: 918-924. Go to original source...
  5. Brennan MJW, Sandyk R, Borsook D. Use of podium valporate in the management of affective disorders: basic and clinical aspect. In: Erich HM, Okuma T, Miller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984: 56-65.
  6. Češková E. Nedoceněný valproát? Čes. A slov. Psychiatr. 97, 2001; 2: 64-68.
  7. Donovan JS, Stewart JW, Nunes EV, Quitkin M, et al. Divalproex treatment for youth with explosive temper and mood lability: A double-blind, placebo-controlled crossover design. The American Journal of Psychiatry. 157, 2000; 5: 818-820. Go to original source... Go to PubMed...
  8. Freeman TW, Clothier JL, Pazzaglia P, et al. A double blind comparison of valproate and lithium in the treatment of acute mania. Am. J. Psychiatry, 1992; 149: 108-111. Go to original source... Go to PubMed...
  9. Hall AC, Brennan A, Goold RG, Cleverley K, Lucas FR, Gordon-Weeks PR, Salinas PC. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Molecular and Cellular Neuroscience 20, 2002: 257-270. Go to original source... Go to PubMed...
  10. Hua LV, Green M, Wong A, Warsh JJ, Li PP. Tetraspan Protein CD151 a common target of mood stabilizing drugs? Neuropsychopharmacology 25, 2001; 5: 729-736. Go to original source... Go to PubMed...
  11. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic depressive illness. Biological Psychiatry, 48, 2000; 18: 740-754. Go to original source... Go to PubMed...
  12. McElroy SL, Keck PE Jr., Pope HG Jr, et al. Valproate in the treatment of rapid-cycling bipolar disorder: J. Clin. Psychopharmacol., 1988; 8: 257-259. Go to original source...
  13. McElroy SL, Keck PE Jr., Stanton SP, et al. Oral loading of divalproex versus haloperidol in the treatment of acute psychotic mania. J. Clin. Psychiatry, 1996; 57: 142-146.
  14. Salomon DA, Ryan CE, Keitner GL, et al. A pilot study of lithium carbonate plus divalproex podium for the continuation and maintanance treatment of patiens with bipolar I. Disorder.: J. Clin. Psychiatry, 1997; 58: 95-99. Go to original source... Go to PubMed...
  15. Sands SA, Guerra V, Morilak DA. Changes in tyroxine hydroxylase mRNA expression in the rat locus coeruleus following acute or chronic treatment with valproic acid. Neuropsychopharmacology 22, 2000; 1: 27-35. Go to original source... Go to PubMed...
  16. Stahl SM. Essentials psychopharmacology. Cambridge: Cambridge University Press, 2000.
  17. Švestka J. Psychofarmaka v klinické praxi. Grada Publishing 1995.




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.